Skip to Content

Vyxeos Approval History

Vyxeos (cytarabine and daunorubicin liposome injection) is a liposomal combination of cytarabine, a nucleoside metabolic inhibitor, and daunorubicin, an anthracycline topoisomerase inhibitor, indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Development History and FDA Approval Process for Vyxeos

Aug  3, 2017Approval FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia
May 31, 2017Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status
Apr  3, 2017Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia
Oct  3, 2016Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017
May 19, 2016Celator Pharmaceuticals Announces Vyxeos Granted Breakthrough Therapy Designation
Mar 14, 2016Celator Announces Phase 3 Trial for Vyxeos™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival
Dec 11, 2012Celator Pharmaceuticals Announces Data on the Effects of CPX-351 in High Risk AML Presented at the ASH Annual Meeting
Jun  5, 2012Celator Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting
Dec 12, 2011Celator Pharmaceuticals and the Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting
Dec  7, 2010Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting
Jun  7, 2010Celator Pharmaceuticals Announces Data on Remissions With CPX-351 Following Induction Failure
May  3, 2010Celator Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.